GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Grifols S.A.
Grifols is a global leader in plasma-based medicines. Its share price is driven by plasma collection volumes and demand for plasma-based immunoglobulins. The chart also reflects recent investor concerns about the company's debt burden and financial transparency.
Share prices of companies in the market segment - Pharma immune
Grifols is a global leader in plasma-based therapies. We classify it as part of the immune pharmaceuticals sector, and the chart below illustrates the overall dynamics of this market, although Grifols has faced challenges related to debt and corporate governance.
Broad Market Index - GURU.Markets
Grifols is a Spanish pharmaceutical company and one of the world's leading manufacturers of plasma-based medications. Its unique niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Grifols compares to the overall market dynamics.
Change in the price of a company, segment, and market as a whole per day
GRFS - Daily change in the company's share price Grifols S.A.
The daily price change of Grifols, a Spanish manufacturer of blood plasma products, reflects the state of its unique business and high debt. Change_co measures volatility associated with plasma collection volumes and investor confidence. This metric is important for formulas on System.GURU.Markets that analyze companies with complex financial structures.
Daily change in the price of a set of shares in a market segment - Pharma immune
Grifols, S.A. is a global leader in the production of plasma-derived products. This chart shows the average daily volatility of the healthcare sector. Comparison with GRFS's performance helps understand its unique and stable, yet capital-intensive, business profile.
Daily change in the price of a broad market stock, index - GURU.Markets
Grifols is a Spanish company and one of the world's leading producers of plasma-based medications. The healthcare sector is considered relatively defensive, but Grifols has faced significant financial challenges. The chart below shows overall market volatility, providing context for assessing Grifols' unique story.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Grifols S.A.
Grifols is a Spanish giant and one of the world's leaders in the production of plasma-derived products. Its year-over-year performance reflects stable demand for its products, as well as its efforts to reduce its debt burden, which has been a focus for investors.
Annual dynamics of market capitalization of the market segment - Pharma immune
Grifols, S.A. is a Spanish company and one of the world's leading producers of plasma-based products. Its plasma-based business is highly stable. The chart below shows how its dominant position, high debt, and efforts to increase transparency impact its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Grifols, a global leader in plasma-derived pharmaceuticals, operates in the defensive sector. However, its recent stock performance reflects not business stability but investor concerns about its debt and accounting practices. The chart tells the story of how corporate governance issues can outweigh fundamental strength.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Grifols S.A.
The value of Grifols, a Spanish manufacturer of plasma-based drugs, depends on plasma collection volumes. Monthly fluctuations on the chart reflect its ability to collect sufficient raw materials to produce its life-saving medications, as well as news related to its high debt load.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Grifols is a global leader in plasma-based medicines. The company's business depends on plasma collection volumes and the demand for its life-saving medications. The dynamics of the biotechnology and plasma-based product sectors reflects overall healthcare trends, allowing for an assessment of operational efficiency and the strategic challenges facing Grifols.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Grifols is a global leader in the production of plasma-based products. This is a specialized and stable healthcare segment. Despite the market fluctuations shown in the chart, Grifols' performance is largely dependent on plasma collection volumes and demand for life-saving products derived from it, making it less cyclical than the overall market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Grifols S.A.
Grifols, a Spanish manufacturer of blood plasma products, shares reflect the state of global healthcare. Weekly price movements depend on plasma collection volumes, demand for immunoglobulins, and corporate governance news. The chart below shows how short-term operational and corporate events impact the company's valuation.
Weekly dynamics of market capitalization of the market segment - Pharma immune
How does Grifols' performance compare to the pharmaceutical sector? The chart below compares the weekly share price movements of the Spanish plasma drug manufacturer with the industry average. This helps us understand how much it is influenced by specific factors (plasma collection, corporate governance) versus general pharmaceutical news.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Grifols is a global leader in plasma-based medicines. It's a stable and vital business. This chart compares its weekly performance to the market to see if its shares are acting as a "safe haven" asset, less susceptible to general economic downturns.
Market capitalization of the company, segment and market as a whole
GRFS - Market capitalization of the company Grifols S.A.
The market capitalization of Grifols, S.A., a global leader in plasma-based medications, reflects stable demand for its products. However, the company's valuation is under pressure from high debt and questions about its financial statements. The chart shows how investors weigh the fundamental strength of the business against corporate risks.
GRFS - Share of the company's market capitalization Grifols S.A. within the market segment - Pharma immune
Grifols, S.A. is a global leader in plasma-based medicines. Its significant market capitalization reflects its critical role in treating rare and chronic diseases. The chart shows how investors assess the demand for its products, as well as its ability to manage a complex network of plasma collection centers.
Market capitalization of the market segment - Pharma immune
The chart below shows the total value of companies producing plasma-derived products. Grifols, S.A. is one of the three global leaders in this vital industry. The dynamics in the chart demonstrate the stability of demand for its products, which cannot be replaced by synthetic alternatives.
Market capitalization of all companies included in a broad market index - GURU.Markets
The graph below visualizes the economic weight of a company built on blood plasma. The market capitalization of Grifols, a global leader in plasma-based medicines, reflects the global need for these vital medications. The line illustrates the unique and irreplaceable role this business plays in global healthcare.
Book value capitalization of the company, segment and market as a whole
GRFS - Book value capitalization of the company Grifols S.A.
This graph shows the value of the physical and intellectual assets of Grifols, S.A., a global leader in plasma-based products. The line represents the value of its network of plasma collection centers, fractionation plants, and patents. The dynamics reflect the investment in this unique and complex value chain.
GRFS - Share of the company's book capitalization Grifols S.A. within the market segment - Pharma immune
Grifols's physical infrastructure consists of a global network of plasma collection centers and factories for processing it into life-saving medications. This unique and complex physical infrastructure is difficult to replicate. The graph shows the significant share of this specialized biopharmaceutical supply chain the company controls.
Market segment balance sheet capitalization - Pharma immune
Grifols is a global leader in the production of blood plasma products. Its business is extremely capital-intensive: it operates a global network of plasma collection centers and massive fractionation plants. The chart below illustrates the colossal foundation of unique medical infrastructure that underpins this entire sector.
Book value of all companies included in the broad market index - GURU.Markets
Grifols' assets include the world's largest network of plasma collection centers and factories for processing it into life-saving medications. The company's book value represents the physical infrastructure that underpins the global plasma-based drug market. The chart illustrates its dominant scale.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Grifols S.A.
Grifols is a global leader in plasma-based medicines. Its balance sheet includes fractionation plants and a network of plasma collection centers. Its market valuation reflects its dominant position in this vital niche, but also concerns about its high debt. The chart shows how the market weighs its operational strength against its financial risks.
Market to book capitalization ratio in a market segment - Pharma immune
Grifols is a global leader in the production of plasma-based products. This is a capital-intensive business, requiring a network of plasma collection centers and processing plants. The chart shows how the market views this vertically integrated model and the demand for the company's vital products.
Market to book capitalization ratio for the market as a whole
Grifols is a global leader in plasma-based medicines. The chart shows how the market values this company, which has a complex and capital-intensive business model, based on the value of its plasma collection centers and manufacturing plants, as well as demand for its life-saving medications, but may be under pressure due to its high debt load.
Debts of the company, segment and market as a whole
GRFS - Company debts Grifols S.A.
Grifols is a global leader in the production of plasma-based products. This business requires a large network of plasma collection centers and sophisticated production facilities. The company's debt burden reflects investments in expanding this vertically integrated structure, as this chart illustrates.
Market segment debts - Pharma immune
Grifols is a global leader in the production of plasma-based products. This process requires the creation and maintenance of a global network of plasma collection centers and sophisticated manufacturing facilities. The chart shows the typical debt burden for the capital-intensive pharmaceutical sector, where investment in vertical integration is key to success.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Grifols S.A.
Grifols is a global leader in the production of plasma-based products. Plasma collection and processing is a complex and capital-intensive process. This chart shows the company's significant debt load, largely due to acquisitions and investments in its plasma collection center network, and is a key factor in its financial health.
Market segment debt to market segment book capitalization - Pharma immune
Grifols is a global leader in the production of plasma-based therapies used to treat rare and chronic diseases. This chart compares the company's debt, required to maintain its network of plasma collection centers and factories, to the total market capitalization of the entire immune pharmaceutical sector. It demonstrates the capital intensity of its unique business.
Debt to book value of all companies in the market
Grifols is a global leader in the production of plasma-derived drugs, which requires enormous capital investment. This chart compares the company's debt to the total book value of the entire economy. It clearly demonstrates the significant financial weight and systemic importance of this unique pharmaceutical giant.
P/E of the company, segment and market as a whole
P/E - Grifols S.A.
This chart shows the valuation of Grifols, S.A., a global leader in plasma-based products. The metric reflects investor confidence in the stability of demand for its vital products. It is sensitive to plasma collection volumes and regulatory changes in the industry.
P/E of the market segment - Pharma immune
This chart shows the average valuation for the biopharma sector, specifically plasma-based drug makers like Grifols. This metric reflects how investors generally value this stable and vital business. It serves as a benchmark for comparing Grifols' valuation to other major players in the healthcare sector.
P/E of the market as a whole
Grifols is a global leader in the production of plasma-based medicines used to treat rare and chronic diseases. The company manages the entire value chain, from plasma collection to finished drug production. This chart helps understand how the market values unique and vital businesses in the healthcare sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Grifols S.A.
Grifols is a global leader in the production of plasma-based medications used to treat rare and chronic diseases. This chart shows market expectations for future plasma collection volumes and demand for life-saving medications derived from them. It assesses the stability and growth of this unique pharmaceutical segment.
%20P%2FE%20Grifols%20S.A.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Grifols-S.A.&v=1772635113099 "Chart of the company's future (projected) P/E Grifols S.A.")
Future (projected) P/E of the market segment - Pharma immune
Grifols is a global healthcare company, a world leader in the production of plasma-based therapies used to treat rare and chronic diseases. The company also provides diagnostic and hospital pharmacy solutions. This chart shows overall market sentiment towards the biotechnology sector, helping to assess Grifols' potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772635113141 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Grifols is one of the world's leading companies producing blood plasma-derived products. Demand for its products is stable and driven by medical needs. Amid market fluctuations, Grifols' key factors include plasma collection volumes, regulatory approvals, and the efficiency of its manufacturing facilities.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772635113164 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Grifols S.A.
Grifols is a global leader in the production of plasma-based therapies used to treat various chronic and rare diseases. The company's profits depend on plasma collection volumes and demand for its life-saving medications. This chart shows how demographic trends and the increasing use of plasma therapy impact financial results.
Profit of companies in the market segment - Pharma immune
Grifols, S.A. is a global leader in plasma-based products and transfusion medicine. This chart shows the overall profitability of the immunology segment. The company's business is critical to the treatment of many rare diseases. Its financial performance depends on plasma collection volumes and demand for its life-saving products.
Overall market profit
Grifols, S.A. is a global leader in the production of plasma-based therapies used to treat rare and chronic diseases. Plasma collection and the demand for life-saving medications make its business resilient to economic cycles. Despite the fluctuations shown in this chart, Grifols plays a critical role in the global healthcare system.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Grifols S.A.
Grifols is a global leader in the production of plasma-based therapies used to treat rare and chronic diseases. Future profit projections, shown in this chart, depend on plasma collection volumes, demand for plasma-based therapies, and the regulatory environment. It shows analysts' assessments of the prospects for this vital healthcare sector.
%20profit%20of%20the%20company%20Grifols%20S.A.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Grifols-S.A.&v=1772635113309 "Graph of future (projected) profit of the company Grifols S.A.")
Future (predicted) profit of companies in the market segment - Pharma immune
Grifols, S.A. is a Spanish pharmaceutical company and one of the world's leading producers of plasma-based products. This chart shows profitability forecasts for the immunology pharmaceutical segment. It reflects expectations for plasma collection volumes and demand for immunoglobulins and other vital proteins.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772635113354 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Grifols, S.A. is a global leader in the production of plasma-based medicines. Demand for its life-saving products is stable and independent of economic cycles. However, the company's operations (plasma collection, plant construction) are capital-intensive. The positive profit outlook reflected here improves access to capital markets, allowing Grifols to finance its expansion.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772635113390 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Grifols S.A.
Grifols, S.A. is a global leader in the production of plasma-based products. The company's revenue depends on plasma collection volumes and demand for its life-saving medications. The P/S ratio reflects how the market perceives its vertically integrated model and the stable demand for its products.
P/S market segment - Pharma immune
Grifols, S.A. is a global leader in the production of plasma-based pharmaceuticals and diagnostic equipment. Their business requires complex plasma collection logistics. This chart shows how investors view their vertically integrated model and dominant position in the vital plasma products market.
P/S of the market as a whole
Grifols is a global leader in the production of plasma-based medicines. The company's revenue is stable, as its products are vital for the treatment of many diseases. This chart illustrates the average revenue estimate, which helps understand the premium the market is willing to pay for this Spanish pharmaceutical company's earnings for stability and niche leadership.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Grifols S.A.
Grifols is a global leader in the production of plasma-based medications used to treat a variety of diseases. The company's business is capital-intensive and requires a large network of plasma collection centers. This chart reflects investor expectations for future sales of these vital medications, for which demand is steadily growing.
%20P%2FS%20Grifols%20S.A.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Grifols-S.A.&v=1772635113595 "The graph of the company's future (projected) P/S Grifols S.A.")
Future (projected) P/S of the market segment - Pharma immune
Grifols, S.A. is a global leader in plasma-based products, such as immunoglobulins, and in transfusion medicine. This chart shows how the market estimates its future sales, dependent on plasma collection and demand for its life-saving products, compared to other immunology companies, reflecting its unique position in healthcare.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772635113686 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Grifols is a global leader in plasma-based therapies. These medications are vital for the treatment of many rare and chronic diseases. The company's business faces a high barrier to entry. This graph shows revenue expectations for the entire market, and Grifols demonstrates how the healthcare sector, which produces essential products, is delivering stable growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772635113712 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Grifols S.A.
Grifols, S.A. is a global leader in the production of plasma-based medicinal products, such as immunoglobulins and albumin, as well as diagnostic equipment for blood banks. This chart shows the revenue from sales of these vital products. Growth depends on plasma collection volumes and global demand for plasma-based products.
Sales of companies in the market segment - Pharma immune
Grifols is a global leader in plasma-based medicines. This chart breaks down its business into key segments: biopharmaceuticals (plasma-based medicines), diagnostics, and biologics. This allows investors to see that the bulk of its revenue is generated by its core, vital business.
Overall market sales
Grifols, S.A. is a global leader in the production of plasma-based therapies. Demand for these vital medications is stable and growing alongside improved diagnostics and an aging population. This general economic activity schedule does not affect Grifols' core business, which is driven by medical needs rather than economic cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Grifols S.A.
Grifols is a global leader in the production of plasma-based medications used to treat rare and chronic diseases. The company's revenue forecast depends on plasma collection volumes and demand for its life-saving medications. This chart shows analysts' expectations for the stability of this unique segment of the pharmaceutical market.
%20sales%20of%20the%20company%20Grifols%20S.A.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Grifols-S.A.&v=1772635113851 "Schedule of future (projected) sales of the company Grifols S.A.")
Future (projected) sales of companies in the market segment - Pharma immune
Grifols is a global leader in plasma-based pharmaceuticals. This chart shows projected revenue for the entire immunology segment. It reflects expected demand for immunoglobulins and other life-saving medications, as well as trends in plasma collection, which are key drivers for Grifols' operations.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772635113863 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Grifols is a global leader in plasma-based therapies used to treat rare and chronic diseases. Demand for its products is stable and unaffected by economic cycles. However, the overall economic situation, as shown in the chart, can impact government healthcare budgets and reimbursement policies, which indirectly impacts the company's business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772635113878 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Grifols S.A.
Grifols is a global leader in plasma-based pharmaceuticals. This chart illustrates profitability in this complex and capital-intensive industry. The company's profitability depends on the cost of plasma collection, fractionation efficiency, and stable global demand for its life-saving products.
Market segment marginality - Pharma immune
Grifols is a global leader in the production of plasma-based medicines and diagnostic equipment. This metric reflects its unique position in the healthcare system. Its high profitability reflects the complexity and capital intensity of its business, creating a high barrier to entry for competitors.
Market marginality as a whole
Grifols, S.A. is a global leader in the production of plasma-based medicines. It's a complex and capital-intensive business, from plasma collection to final drug production. This overall profitability chart reflects the state of the economy, but for Grifols, demographic trends, donor access, and the healthcare regulatory environment are more important.
Employees in the company, segment and market as a whole
Number of employees in the company Grifols S.A.
Grifols is a global leader in plasma-based products and transfusion medicine. Its vast workforce includes personnel at plasma collection centers, manufacturing facilities, and laboratories. This chart reflects the scale of its vertically integrated business model, which is critical to healthcare.
Share of the company's employees Grifols S.A. within the market segment - Pharma immune
Grifols, S.A. is a global leader in plasma-based pharmaceuticals and transfusion medicine. This chart demonstrates its dominance in this vital niche. It reflects the significant share of biochemists, plasma fractionation specialists, and staff at Grifols' global plasma collection centers.
Number of employees in the market segment - Pharma immune
Grifols, S.A. is a global leader in the production of plasma-based products. This chart shows employment in the immunology and biotechnology sector. The growing number of specialists in this field indicates high demand for life-saving medications for the treatment of immunodeficiency and other rare diseases, necessitating the expansion of the plasma collection center network.
Number of employees in the market as a whole
Grifols is a global leader in the production of plasma-based medicines. The growth of its plasma collection centers and manufacturing facilities reflects the growing demand for life-saving medications. The company is a key player in the global healthcare system, providing stable employment in a unique medical niche.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Grifols S.A. (GRFS)
Grifols is a global leader in the production of plasma-based medications. Their business is vertically integrated, from plasma collection to drug production and distribution. This requires both a large number of personnel at collection centers and capital-intensive manufacturing facilities. This graph reflects the balance between these two factors, showing a moderately high figure.
%20of%20the%20company%20Grifols%20S.A.%20(GRFS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Grifols-S.A.-GRFS&v=1772635114037 "Chart of market capitalization per employee (in thousands of dollars) of the company Grifols S.A. (GRFS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Grifols is a global leader in plasma-based products. It's a unique, vertically integrated business, spanning from plasma collection (labor-intensive) to fractionation (capital-intensive). This chart shows the industry average, helping to assess how the market values this complex yet vital business model per employee.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772635114058 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Grifols is a global leader in the production of plasma-based products used to treat a variety of diseases. Plasma collection and processing is a complex and highly regulated process. This chart reflects how the market evaluates the company's ability to manage this unique vertically integrated model.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772635114085 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Grifols S.A. (GRFS)
Grifols is a Spanish company and one of the world's leading producers of plasma-based products (albumin, immunoglobulins). The business is vertically integrated, from plasma collection to drug production. This chart shows how efficiently the company manages this complex and expensive chain (plasma collection is a labor-intensive process).
%20Chart%20Grifols%20S.A.%20(GRFS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Grifols-S.A.-GRFS&v=1772635114092 "Company Profit Per Employee (in thousands of dollars) Chart Grifols S.A. (GRFS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Grifols is a global leader in plasma-based products. It's a vertically integrated business (plasma collection and processing). This chart shows the benchmark for Immuno-Pharma. In this B2B sector, the benchmark is moderate. It's a manufacturing business, where profit per employee depends on the efficiency of collection (centers) and fractionation (plants).
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772635114099 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Grifols is a Spanish company and one of the world's leading manufacturers of blood plasma-based products (albumin, immunoglobulins). It is a vertically integrated business (from plasma collection to medications). This chart, showing the average market profitability per employee, helps us understand how efficient the complex blood plasma sector is.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772635114140 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Grifols S.A. (GRFS)
Grifols, S.A., a global leader in plasma-based medicines, demonstrates the effectiveness of its vertically integrated model in this chart. Revenue per employee depends on plasma collection, fractionation efficiency, and sales of end products. This growth reflects the global demand for its life-saving medications.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Grifols-S.A.-GRFS&v=1772635114172 "Sales chart per company employee Grifols S.A. (GRFS)")
Sales per employee in the market segment - Pharma immune
Grifols is a global leader in plasma-based drug production. Their business is vertically integrated, from plasma collection centers to drug manufacturing. This chart shows the average revenue per employee in this segment. It reflects how efficiently Grifols manages this complex value chain compared to its biotech competitors.
Sales per employee for the market as a whole
Grifols (GRFS) is a global leader in the production of plasma-based products. This is a complex and capital-intensive biomedical business, requiring both plasma collection (labor-intensive) and fractionation (capital-intensive). This metric reflects the efficiency of the entire vertically integrated supply chain—from donor to finished product.
Short shares by company, segment and market as a whole
Shares shorted by company Grifols S.A. (GRFS)
Grifols, S.A. is a Spanish company and one of the world's leading producers of plasma-based medications. The company recently came under attack from short sellers due to accusations of opaque reporting. This chart shows that many investors believe these accusations and are betting that the company has serious debt and financial structure issues.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Grifols-S.A.-GRFS&v=1772635114233 "Short Shares Chart for the Company Grifols S.A. (GRFS)")
Shares shorted by market segment - Pharma immune
Grifols is a Spanish company and one of the world's leading producers of plasma-based products. Its business depends on plasma collection and pricing. This chart highlights the pessimism in the sector. The increase in short positions across the industry may reflect concerns about the company's high debt load or regulatory pressure on plasma collection centers in the US.
Shares shorted by the overall market
Grifols (GRFS) is a global leader in plasma-based medications, such as immunoglobulin. These are critically important drugs for the treatment of rare diseases. This chart illustrates the overall market pessimism. Although demand for Grifols' products is stable (it's in a defensive sector), the company has historically had high debt. Rising market fears are making investors very nervous about the company's ability to service this debt.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Grifols S.A. (GRFS)
Grifols is a Spanish leader in the production of blood plasma products. The company is facing questions about its financial statements and debt. This chart above 70 may reflect a temporary restoration of confidence. A level below 30 is often associated with concerns about debt, competition, or problems with plasma collection.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Grifols-S.A.-GRFS&v=1772635114289 "RSI 14 indicator chart for the company's stock Grifols S.A. (GRFS)")
RSI 14 Market Segment - Pharma immune
Grifols, S.A. is a Spanish company and a global leader in the production of plasma-based medicines used to treat rare and chronic diseases. It also produces diagnostic equipment. This chart measures the overall momentum in the unique plasma therapy sector. It shows how investors value this industry, which relies on plasma collection and pricing.
RSI 14 for the overall market
Grifols, a Spanish manufacturer of plasma-based medications, sees debt-related risks in this chart. Demand for its immunoglobulin product is stable. However, market turmoil and rising interest rates are sharply increasing the cost of servicing its massive debt, calling into question the company's financial sustainability.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GRFS (Grifols S.A.)
Grifols (GRFS) is a global leader in the production of plasma-based medications (immunoglobulins, albumin). The company operates plasma collection centers in the US and Europe. The chart shows analyst consensus forecasts. It shows their assessment of plasma collection volumes, demand for these medications, and investor concerns about the company's high debt.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GRFS-Grifols-S.A.&v=1772635114334 "A chart showing analyst consensus forecasts for the expected stock price. GRFS (Grifols S.A.)")
The difference between the consensus estimate and the actual stock price GRFS (Grifols S.A.)
Grifols is a Spanish company and a global leader in the production of blood plasma-derived medications (immunoglobulins, albumin). The company operates a network of donor centers. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the consensus price forecast and the current price, reflecting confidence in the plasma market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GRFS-Grifols-S.A.&v=1772635114342 "A chart showing the difference between the consensus forecast and the actual stock price. GRFS (Grifols S.A.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Grifols is a global leader in the production of plasma-derived medications (albumin, immunoglobulin). The company's business involves collecting and processing plasma in the United States. This chart shows analysts' general expectations for the immunology sector. It reflects whether experts believe demand for these vital medications will grow.
Analysts' consensus forecast for the overall market share price
Grifols (GRFS) is a Spanish giant, one of the oligopolies in the blood plasma industry. They collect plasma and use it to make life-saving medications. This graph, reflecting expert expectations, doesn't affect their demand. However, it does affect their donors. During a recession (pessimism), people (especially in the US) may donate plasma more actively (to earn money), which reduces their costs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Grifols S.A.
Grifols is a Spanish giant, one of the world's top three plasma-based drug manufacturers. They collect blood plasma and fractionate it into life-saving medications. This chart is an indicator of the plasma market. It likely aggregates plasma collection volumes (and costs), demand for their products (immunoglobulin), and their recent problems with high debt.
AKIMA Market Segment Index - Pharma immune
Grifols (GRFS) is a global leader (one of three) in the blood plasma industry; the company collects plasma (through centers in the US) and produces life-saving medications (immunoglobulin) from it. This comprehensive index evaluates companies. The graph shows the sector average. This benchmark: how does Grifols' vertically integrated (collection + production) model differentiate it from the average competitor?
The AKIM Index for the overall market
Grifols is a Spanish blood plasma giant. The company (like CSL) collects plasma and produces medicines (immunoglobulins) from it. It's a defensive (non-cyclical) business. This chart, reflecting the market average, is a backdrop. It helps assess how Grifols, which operates within its own cycle, compares to general macroeconomic fluctuations.
